Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.

MLA

Ikeda, Takanori, et al. “Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.” The Tohoku Journal of Experimental Medicine, vol. 240, no. 4, Dec. 2016, pp. 259–68. EBSCOhost, https://doi.org/10.1620/tjem.240.259.

APA

Ikeda, T., Atarashi, H., Inoue, H., Uchiyama, S., Kitazono, T., Yamashita, T., Shimizu, W., Kamouchi, M., Kaikita, K., Fukuda, K., Origasa, H., Sakuma, I., Saku, K., Okumura, Y., Nakamura, Y., Morimoto, H., Matsumoto, N., Tsuchida, A., Ako, J., … Shimokawa, H. (2016). Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. The Tohoku Journal of Experimental Medicine, 240(4), 259–268. https://doi.org/10.1620/tjem.240.259

Chicago

Ikeda, Takanori, Hirotsugu Atarashi, Hiroshi Inoue, Shinichiro Uchiyama, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, et al. 2016. “Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.” The Tohoku Journal of Experimental Medicine 240 (4): 259–68. doi:10.1620/tjem.240.259.